Intellia Therapeutics Inc reports results for the quarter ended in September 30 - Earnings Summary

• Intellia Therapeutics Inc NTLA.OQ reported a quarterly adjusted loss of $1.34​​ per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of $-1.38. The mean expectation of twenty seven analysts for the quarter was for a loss of $1.38 per share. Wall Street expected results to range from $-1.57 to $-1.06 per share.

• Revenue fell 24% to $9.11 million from a year ago; analysts expected $7.86 million.

• Intellia Therapeutics Inc's reported EPS for the quarter was a loss of $1.34​.

• The company reported a quarterly loss of $135.71 million.

• Intellia Therapeutics Inc shares had fallen by 21.8% this quarter and lost 47.3% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 0.4% in the last three months.​

• In the last 30 days, one analyst negatively revised an earnings estimate

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 23 "strong buy" or "buy," 6 "hold" and no "sell" or "strong sell."

• The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for Intellia Therapeutics Inc is 62.00

This summary was machine generated from LSEG data November 7 at 03:10 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)